Solid Biosciences (SLDB) Depreciation & Amortization (CF) (2017 - 2026)
Solid Biosciences (SLDB) reported Depreciation & Amortization (CF) of $395000.0 for Q1 2026, down 2.95% on a YoY basis from $407000.0 in Q1 2025, and down 15.42% sequentially from $467000.0 in Q4 2025.
Solid Biosciences (SLDB) Depreciation & Amortization (CF) (2017 - 2026) Analysis & Trends
Solid Biosciences (SLDB) has 10 years of Depreciation & Amortization (CF) data on file, last reported at $395000.0 in Q1 2026.
- For the quarter ending Q1 2026, Depreciation & Amortization (CF) fell 2.95% year-over-year to $395000.0; the trailing twelve-month figure through Mar 2026 stood at $1.6 million (down 35.94% YoY), and the FY2025 full-year result was $1.6 million, down 33.36% from the prior year.
- Depreciation & Amortization (CF) fell to $395000.0 in Q1 2026, from $467000.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $1.2 million in Q2 2024 to a low of $327000.0 in Q1 2024.
- A 5-year average of $557352.9 and a median of $488000.0 in 2024 frame the typical range for Depreciation & Amortization (CF).
- Across the five-year window, Depreciation & Amortization (CF) jumped 75.68% in 2024 and plunged 68.74% in 2025, its largest moves.
- Tracing SLDB's Depreciation & Amortization (CF) over 5 years: stood at $539000.0 in 2022, then grew by 8.91% to $587000.0 in 2023, then fell by 16.87% to $488000.0 in 2024, then declined by 4.3% to $467000.0 in 2025, then declined by 15.42% to $395000.0 in 2026.
- Business Quant data shows SLDB's Depreciation & Amortization (CF) at $395000.0 in Q1 2026, $467000.0 in Q4 2025, and $376000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 196,658.72 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 41.14 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 91,781.47 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 55.90 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 123.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 2.20 Mn |
| 10 | Solid Biosciences | 529.40 Mn | 529.40 Mn | - | 395,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 395,000.00 |
| Mar 31, 2026 | 395,000.00 |
| Dec 31, 2025 | 467,000.00 |
| Dec 31, 2025 | 467,000.00 |
| Sep 30, 2025 | 376,000.00 |
| Sep 30, 2025 | 376,000.00 |
| Jun 30, 2025 | 386,000.00 |
| Jun 30, 2025 | 386,000.00 |
| Mar 31, 2025 | 407,000.00 |
| Mar 31, 2025 | 407,000.00 |
| Dec 31, 2024 | 488,000.00 |
| Dec 31, 2024 | 488,000.00 |
| Sep 30, 2024 | 405,000.00 |
| Sep 30, 2024 | 405,000.00 |
| Jun 30, 2024 | 1.24 Mn |
| Jun 30, 2024 | 1.24 Mn |
| Mar 31, 2024 | 327,000.00 |
| Mar 31, 2024 | 327,000.00 |
| Dec 31, 2023 | 587,000.00 |
| Dec 31, 2023 | 587,000.00 |